Cargando…

Recycling side-effects into clinical markers for drug repositioning

Side-effects are the unintended consequence of therapeutic treatments, but they can also be seen as valuable read-outs of drug effects in humans; these effects are difficult to infer or predict from pre-clinical models. Indeed, some studies suggest that drugs with similar side-effect profiles may al...

Descripción completa

Detalles Bibliográficos
Autores principales: Duran-Frigola, Miquel, Aloy, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334551/
https://www.ncbi.nlm.nih.gov/pubmed/22283977
http://dx.doi.org/10.1186/gm302
_version_ 1782230637913047040
author Duran-Frigola, Miquel
Aloy, Patrick
author_facet Duran-Frigola, Miquel
Aloy, Patrick
author_sort Duran-Frigola, Miquel
collection PubMed
description Side-effects are the unintended consequence of therapeutic treatments, but they can also be seen as valuable read-outs of drug effects in humans; these effects are difficult to infer or predict from pre-clinical models. Indeed, some studies suggest that drugs with similar side-effect profiles may also share therapeutic properties through related mechanisms of action. A recent publication exploits this concept to systematically investigate new indications for already marketed drugs, and presents a strategy to get the most out of the tiny portion of chemicals that have proved to be effective and safe.
format Online
Article
Text
id pubmed-3334551
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33345512013-01-27 Recycling side-effects into clinical markers for drug repositioning Duran-Frigola, Miquel Aloy, Patrick Genome Med Research Highlight Side-effects are the unintended consequence of therapeutic treatments, but they can also be seen as valuable read-outs of drug effects in humans; these effects are difficult to infer or predict from pre-clinical models. Indeed, some studies suggest that drugs with similar side-effect profiles may also share therapeutic properties through related mechanisms of action. A recent publication exploits this concept to systematically investigate new indications for already marketed drugs, and presents a strategy to get the most out of the tiny portion of chemicals that have proved to be effective and safe. BioMed Central 2012-01-27 /pmc/articles/PMC3334551/ /pubmed/22283977 http://dx.doi.org/10.1186/gm302 Text en Copyright ©2012 BioMed Central Ltd.
spellingShingle Research Highlight
Duran-Frigola, Miquel
Aloy, Patrick
Recycling side-effects into clinical markers for drug repositioning
title Recycling side-effects into clinical markers for drug repositioning
title_full Recycling side-effects into clinical markers for drug repositioning
title_fullStr Recycling side-effects into clinical markers for drug repositioning
title_full_unstemmed Recycling side-effects into clinical markers for drug repositioning
title_short Recycling side-effects into clinical markers for drug repositioning
title_sort recycling side-effects into clinical markers for drug repositioning
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334551/
https://www.ncbi.nlm.nih.gov/pubmed/22283977
http://dx.doi.org/10.1186/gm302
work_keys_str_mv AT duranfrigolamiquel recyclingsideeffectsintoclinicalmarkersfordrugrepositioning
AT aloypatrick recyclingsideeffectsintoclinicalmarkersfordrugrepositioning